PetCaseFinder

Peer-reviewed veterinary case report

Blood clotting test results in dogs with chronic liver disease

By Fry, W et al.·Published in Journal of veterinary internal medicine·2017·Massachusetts Veterinary Referral Hospital, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Thromboelastography in Dogs with Chronic Hepatopathies.

Species:
dog
Stomach & digestionDogs

Plain-English summary

A group of 21 dogs with chronic liver disease (hepatopathies) underwent a special blood test called thromboelastography (TEG) to assess their blood clotting ability. The results showed that many of these dogs had abnormal clotting profiles, which could indicate a worse prognosis. Specifically, some dogs were found to have a higher risk of bleeding due to low clotting factors. The study highlighted that dogs with more severe liver disease had more significant changes in their TEG results, which could help veterinarians predict complications and tailor treatments accordingly.

People also search for: dog liver disease symptoms · chronic hepatopathy in dogs · dog blood clotting tests · liver disease treatment for dogs

Abstract

BACKGROUND: The coagulation status of dogs with liver disease is difficult to predict using conventional coagulation testing. HYPOTHESIS/OBJECTIVES: To evaluate thromboelastography (TEG) results and associations with conventional coagulation results and indicators of disease severity and prognosis in dogs with chronic hepatopathies (CH). ANIMALS: Twenty-one client-owned dogs. METHODS: Dogs with CH were prospectively (10 dogs) and retrospectively (11 dogs) enrolled from 2008 to 2014. Kaolin-activated TEG was performed and compared with reference intervals by t-tests or Mann-Whitney tests. Correlation coefficients for TEG results and conventional coagulation and clinicopathologic results were determined. Significance was set at P < .05. RESULTS: Dogs with CH had significant increases in R (5.30 min vs 4.33 min), K (3.77 min vs 2.11 min), and LY30 (4.77% vs 0.68%) and decreased angles (55.3&#xb0; vs 62.4&#xb0;). G value defined 9 of 21, 7 of 21, and 5 of 21 dogs as normocoagulable, hypercoagulable, and hypocoagulable, respectively. G and MA were correlated with fibrinogen (r = 0.68, 0.83), prothrombin time (PT; r = -0.51, -0.53), and activated partial thromboplastin time (aPTT; r = -0.50, -0.50). K was correlated with PT (r = 0.75) and protein C activity (r = -0.92). Angle was correlated with aPTT (r = -0.63). Clinical score was correlated with PT (r = 0.60), MA (r = -0.53), and R (r = -0.47). Dogs with hyperfibrinolysis (LY30 > 3.04%; 5 of 21) had significantly higher serum transaminase activities. Dogs with portal hypertension had significantly lower G, MA, and angle and prolonged, K, R, and PT. CONCLUSIONS AND CLINICAL RELEVANCE: Dogs with CH have variable TEG results. Negative prognostic indicators in CH correlate with hypocoagulable parameters on TEG. Hyperfibrinolysis in dogs with CH is associated with high disease activity.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28097681/